Genstar Capital-backed Advarra completed the acquisition of Forte Group from Primus Capital for $40m.

Genstar Capital-backed Advarra, the premier provider of institutional review board, institutional biosafety committee, and research quality and compliance consulting services, acquired Forte Group, a provider of standards-based clinical research technology solutions, from Primus Capital for $40m. "Forte is known across the research community as the gold standard for eClinical technology solutions. Their organizational culture and values are the perfect complement to Advarra's 'altogether better' approach to advancing clinical research. We look forward to collaborating with Forte's customers and team members to continue to enhance their outstanding products and services with additional investment to serve our mutual clients," Pat Donnelly, Advarra CEO.